Rocket Lab's Neutron Tank Flaw Pushes First Launch to 2027 as Losses Balloon
Published on 11/12/2026 at 14:11 | Editorial boerse-global.de
Rocket Lab investors got two pieces of bad news in the same week — and they arrived from opposite ends of the business. A manufacturing defect in a composite tank dome on Neutron's first stage has pushed the rocket's debut to 2027, while third-quarter results showed a net loss that widened sharply from a year earlier. The stock slipped 2.7% in pre-market trading, with the day's move later measured at -3.0%.
The flaw involves voids discovered in the composite structure of the tank dome. The delay gives the company's cost base another year to run ahead of its first Neutron revenue, and it lands just as the financial statements are already under strain.
The Street Splits on What the Delay Is Worth
Piper Sandler cut its price target on Tuesday from $83 to $58 while keeping a neutral rating, citing the uncertain Neutron schedule alongside lower valuation multiples across the space sector. Morgan Stanley trimmed its own target a day earlier, though far more modestly — to $103 from $105 — and held firm on its overweight rating. Two houses, two very different readings of the same setback.
A Record Top Line With a Heavier Bottom Line
For the third quarter of 2026, Rocket Lab posted revenue of $268 million, a company record. The GAAP loss came in at $0.12 per share. The net loss reached $79.677 million, roughly four times the $18.257 million recorded in the same period a year earlier. Media coverage of the results flagged both the slipped Neutron debut and a wider-than-expected adjusted loss as drags on the shares.
Should investors sell immediately? Or is it worth buying Rocket Lab?
Management's outlook for the fourth quarter points to revenue of $270 million to $290 million — a range that reportedly topped analyst expectations — together with an anticipated improvement in gross margin. The adjusted EBITDA loss is guided to between $14 million and $20 million.
Why the Margin Matters More Than the Revenue Number
The fourth-quarter targets only carry weight in combination. Revenue at the top of the range would mean little if the margin fails to expand and the EBITDA loss settles at the wrong end of guidance. A result near the $14 million mark would support the case that growth is becoming more economical; a figure closer to $20 million would suggest the top line is still being bought at a heavy price.
That distinction matters because the adjusted EBITDA outlook and the net loss measure different things. Investors tracking the story need to watch both the operating guidance and the all-in result — a widening gross margin counts as progress only if it feeds through to the operating line.
The Backlog Is Real — the Question Is What It Earns
Underpinning the bull case is a record order book of $3.57 billion. On Monday, Rocket Lab also announced eight Neutron missions for five satellite-constellation operators, agreements valued at more than $515 million. Several of those launches were contracted at a base price of $70 million, and the company raised that base price for multiple missions — a move that could lift the economics of future flights, provided cost inflation doesn't eat the gain. Neutron's backlog now stands at 16 missions.
Contracts, of course, describe future business rather than current profit. The backlog gains real weight for valuation only if it converts at better margins. Demand, pricing and margin progress reinforcing one another would be a stronger argument than any single revenue record, because it would rest on a broader base for eventual profitability.
Rocket Lab at a turning point? This analysis reveals what investors need to know now.
The Fourth Quarter Is the Next Reckoning
The central risk is a repeat of the same pattern: strong commercial momentum paired with weak bottom-line delivery. If that combination persists, the backlog story has to be weighed against losses that are actually being incurred. Should the revenue climb arrive alongside a higher gross margin and an EBITDA loss at the favorable end of guidance, the optimistic case holds together. Should the mix tilt toward heavier charges instead, the loss risk takes on more weight.
Until then, shareholders face a straightforward choice — extend credit to the order momentum now, or wait for evidence that the growth is finally being converted into something the income statement can show.
Ad
Rocket Lab Stock: New Analysis - 12 November
Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
